Pfizer Advances in Cancer Cell Therapy with Allogene Agreement – Market Realist
Market Realist |
Pfizer Advances in Cancer Cell Therapy with Allogene Agreement
Market Realist According to the terms of the agreement, upon completion of the transaction, Allogene has rights to Pfizer’s 16 pre-clinical CAR–T assets. Those assets are licensed from Servier, a French pharmaceutical company; Cellectis (CLLS), a French cell therapy … |
|
Scientists unlock path to use cell’s own nanoparticles as disease biomarkers
Science Daily He said it will also allow scientists to engineer EVs for use in tissue regeneration and help start a new chapter in stem–cell therapies and regenerative medicine. “The human body naturally directs EVs from stem cells to damaged tissue to assist in its … |
Proactive Investors UK |
WideCells establishes ‘end-to-end’ stem cell service
Proactive Investors UK CellPlan is a stem cell healthcare insurance plan that makes stem cell transplants affordable for families who require treatment for life-threatening diseases. WideCells Group Science focuses on stem cell research and stem cell storage. Wideacademy … |